Organon (OGN) closed at $11.30 in the latest trading session, marking a +1.07% move from the prior day. The stock exceeded the S&P 500, which registered a gain of 0.79% for the day. Elsewhere, the Dow ...

Organon (OGN) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of ...

Mucinex maker Reckitt Beckiser’s new “simpler and more effective organization” won’t include 190 New Jersey workers. | ...

During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in ...

Organon, a women’s health-focused pharma company based in Jersey City, expects to eliminate 93 jobs as part of an effort to optimize internal operations. In a filing with the state Department of Labor ...

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same ...

Tofidence is indicated in certain patients for the treatment of moderate to severe rheumatoid arthritis, giant cell arteritis ...

Organon OGN shares soared 8.5% in the last trading session to close at $12.64. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to ...

Learn more about whether Organon & Co. or Viatris Inc. is a better investment based on AAII's A+ Investor grades, which ...

Organon (OGN) announced that it has acquired from Biogen (BIIB) regulatory and commercial rights in the U.S. for Tofidence, a biosimilar to ...

The revision of the outlook to negative is due to the anticipation that Organon’s leverage will continue to be high over the next 12-18 months. This is attributed to limited near-term earnings growth ...

Organon Canada, a global healthcare company with a mission to improve the health of women throughout their lives, today announced that Health Canada has approved NDUVRA (tapinarof cream), 1%, the ...